Littlejohns, Thomas J. http://orcid.org/0000-0003-1177-6923
Holliday, Jo
Gibson, Lorna M.
Garratt, Steve http://orcid.org/0000-0001-9638-4173
Oesingmann, Niels
Alfaro-Almagro, Fidel
Bell, Jimmy D. http://orcid.org/0000-0003-3804-1281
Boultwood, Chris
Collins, Rory
Conroy, Megan C. http://orcid.org/0000-0002-3847-6202
Crabtree, Nicola http://orcid.org/0000-0001-6729-5841
Doherty, Nicola
Frangi, Alejandro F. http://orcid.org/0000-0002-2675-528X
Harvey, Nicholas C.
Leeson, Paul http://orcid.org/0000-0001-9181-9297
Miller, Karla L.
Neubauer, Stefan
Petersen, Steffen E. http://orcid.org/0000-0003-4622-5160
Sellors, Jonathan
Sheard, Simon http://orcid.org/0000-0002-8925-8280
Smith, Stephen M. http://orcid.org/0000-0001-8166-069X
Sudlow, Cathie L. M.
Matthews, Paul M. http://orcid.org/0000-0002-1619-8328
Allen, Naomi E. http://orcid.org/0000-0003-1938-5038
Article History
Received: 18 March 2019
Accepted: 3 April 2020
First Online: 26 May 2020
Competing interests
: Nicholas C. Harvey acknowledges consultancy/grant support/honoraria from Alliance for Better Bone Health, AMGEN, UCB, Radius Health, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare and Internis Pharma, outside the submitted work. Paul Leeson acknowledges grant support from Lantheus Medical Imaging and Fukuda, consultancy fees from Intelligent Ultrasound and is a non-executive director of Ultromics. Steffen E. Petersen acknowledges consultancy fees from Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada. Paul Matthews acknowledges consultancy fees from Roche, Adelphi Communications, Celgene and Biogen. He has received honoraria or speakers’ honoraria from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and Nodthera. He is a member of the Scientific Advisory Board to the Board of Ipsen Pharmaceuticals. The remaining authors declare no competing interests.